# A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

> **NCT06313593** · PHASE1 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 186 (estimated)

## Conditions studied

- Myeloproliferative Neoplasms

## Interventions

- **DRUG:** INCB160058
- **DRUG:** Standard disease-directed therapy

## Key facts

- **NCT ID:** NCT06313593
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2028-10-09
- **Final completion:** 2028-10-09
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313593, "A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06313593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*